PMID- 24287690
OWN - NLM
STAT- MEDLINE
DCOM- 20150408
LR  - 20221207
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 30
IP  - 12
DP  - 2013 Dec
TI  - The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in 
      challenging patient groups.
PG  - 1067-85
LID - 10.1007/s12325-013-0071-y [doi]
AB  - Treating hyperglycemia is a critical aspect of managing type 2 diabetes mellitus 
      (T2DM), but can be especially challenging in patients from vulnerable groups such 
      as those with chronic kidney disease, African Americans, and older people. The 
      dipeptidyl peptidase (DPP)-4 inhibitors are relatively new oral antidiabetes 
      drugs that have been incorporated into treatment algorithms over the past few 
      years and have also been studied in these vulnerable patients. Clinical trials 
      with DPP-4 inhibitors have now been reported for all these patient groups and 
      have demonstrated significant improvements in measures of hyperglycemia, with a 
      good safety profile. Based on the current evidence, it appears that the DPP-4 
      inhibitors are worthy of consideration not only for the most straightforward 
      patients with T2DM, but also for these vulnerable patients.
FAU - Kountz, David
AU  - Kountz D
AD  - Jersey Shore University Medical Center, Rutgers-Robert Wood Johnson Medical 
      School, 1945 State Route 33, PO Box 397, Neptune, NJ, 07754-0397, USA, 
      dkountz@meridianhealth.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131128
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
MH  - Administration, Oral
MH  - Black or African American/statistics & numerical data
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/analysis/*drug effects
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - Prognosis
MH  - Renal Insufficiency, Chronic/diagnosis/epidemiology
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Vulnerable Populations/*statistics & numerical data
PMC - PMC3898344
EDAT- 2013/11/30 06:00
MHDA- 2015/04/09 06:00
PMCR- 2013/11/28
CRDT- 2013/11/30 06:00
PHST- 2013/08/09 00:00 [received]
PHST- 2013/11/30 06:00 [entrez]
PHST- 2013/11/30 06:00 [pubmed]
PHST- 2015/04/09 06:00 [medline]
PHST- 2013/11/28 00:00 [pmc-release]
AID - 71 [pii]
AID - 10.1007/s12325-013-0071-y [doi]
PST - ppublish
SO  - Adv Ther. 2013 Dec;30(12):1067-85. doi: 10.1007/s12325-013-0071-y. Epub 2013 Nov 
      28.